By encapsulating siRNA nanoparticles targeting FAISL, silencing FAISL reduces the expression of FAK protein and inhibits the tumor growth and metastasis of TNBC cells in vivo. This evidence concerns the gene VPS9D1-AS1 and neoplasm.